

# Clinical efficacy of Faropenem in different diseases & therapeutic areas

Therapeutic area	Disease	Rate of efficacy in therapeutic area (%)	Rate of efficacy in disease (%)
Surgical	mastitis	<b>98.04 %</b>	97.67 %
	periproctal abscess		96.23 %
	secondary infection of external wounds, burns and operation incisions		98.60 %
Respiratory	pharyngolaryngitis	<b>95.07 %</b>	95.87 %
	acute bronchitis		94.12 %
	tonsillitis		96.16 %
	pneumonia		87.54 %
Urinary tract	pyelonephritis	<b>94.35 %</b>	92.99 %
	cystitis		95.05 %
	prostatitis		89.19 %
	epididymitis		94.12 %
Gynecological	adnexitis	<b>96.72 %</b>	95.83 %
	intrauterine infection		97.41 %
	bartholinitis		98.04 %
Otorhinolaryngeal	otitis externa	<b>91.11%</b>	91.37 %
	otitis media		90.08 %
	sinusitis		91.80 %
	Superficial suppurative		acne pustular
acne conglobata		85.00 %	
folliculitis		95.08 %	
furunculosis		92.98 %	
carbuncles		96.67 %	
impetigo contagiosa		96.36 %	
erysipelas		100.00%	
phlegmon		96.92 %	
lymphangitis (lymphadenitis)		96.43 %	
whitlow		96.43 %	
suppurative onychia (paronychia)		96.12 %	
subcutaneous abscess		96.03 %	
infectious atheroma		96.79%	
Dental and oral Surgical		inflammation of periodontal tissue	<b>98.6%</b>
	pericoronitis	99.07 %	
	inflammation of the jaw	98.78 %	

Ref: 1.Kubota H, Tei S, Hikida A, Funahashi K, Komano N, Kubota Y, Kajiura T. Faropenem [Use-results surveillance of Faropenem (FRPM) tablets]. (Japanese Journal of Chemotherapy). 2002; 50(11):809-825. DOI: 10.11250/chemotherapy1995.50.809

Brought to you by



Faropenem 150 mg & 200 mg Tablet



For full Article

# Therapeutic effectiveness of Faropenem against key Infectious bacterias



Faropenem 150 mg & 200 mg Tablet

Bacterial species		Rate of efficacy in disease (%)	
Gram-positive bacteria	Staphylococcus sp. [MRSA included]	94. 12 (352/374)	<b>【65. 52 (19/29)】</b>
	Streptococcus sp.	94. 30	(215/228)
	Streptococcus pneumoniae.	86. 67	(39/45)
	Enterococcus faecalis.	93. 33	(56/60)
	other gram-positive bacterias.	92. 65	(126/136)
Gram-negative bacteria	Moraxella (Branhamella) catarrhalis.	100. 0	(12/12)
	Escherichia coli.	96. 64	(403/417)
	Citrobacter sp.	100. 0	(16/16)
	Klebsiella sp.	98. 44	(63/64)
	Enterobacter sp.	90. 48	(19/21)
	Proteus mirabilis.	100. 0	(15/15)
	Haemophilus influenzae	90. 48	(38/42)
	Other gram-negative bacterias.	82. 96	(185/223)
Anaerobes	Peptostreptococcus sp.	—	(9/9)
	Propionibacterium acnes	—	(0/1)
	Bacteroides sp.	100. 0	(11/11)
	Other anaerobic bacterias.	—	(5/6)
Unidentified bacteria, fungi, etc.		87. 50	(21/24)

Indication	Dosage
Upper Respiratory Tract Infections	150 mg t.i.d., can be increased to 200 mg t.i.d.
ENT Infections	200 mg t.i.d., can be increased to 300 mg t.i.d.
Lower Respiratory Tract Infections	200 mg t.i.d., can be increased to 300 mg t.i.d.
Skin and Skin Structure Infections	150 mg t.i.d., can be increased to 200 mg t.i.d.
Genito-Urinary Infections	200 mg t.i.d., can be increased to 300 mg t.i.d.
Gynecological Infections	150 mg t.i.d., can be increased to 200 mg t.i.d.

Ref: 1.Kubota H, Tei S, Hikida A, Funahashi K, Komano N, Kubota Y, Kajjura T. Faropenem [Use-results surveillance of Faropenem (FRPM) tablets]. (Japanese Journal of Chemotherapy). 2002; 50(11):809-825. DOI: 10.11250/chemotherapy1995.50.809



For full prescribing information



Nuvista Pharma (a subsidiary of Beximco Pharma)  
 Dhaka-1216, Bangladesh | www.nuvistapharma.com | f nuvistapharma

FAR-MCRC120426MJU-SPN/SDA